Comparison of radiofrequency ablation combined with sorafenib or sorafenib alone in patients with ECOG performance score 1: identifying optimal candidates

BACKGROUND: Sorafenib has been recommended as the first-line treatment and shown to prolong the median overall survival (OS) of patients with advanced unresectable hepatocellular carcinoma (HCC). Recently, a growing number of earlier studies showed the application of radiofrequency ablation (RFA) pl...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Ann Transl Med
Glavni autori: Liu, Lei, Zhang, Qian, Geng, Jie, Li, Songlun, Zhao, Shoujie, Zhang, Xiangnan, Hu, Jie, Feng, Dayun
Format: Artigo
Jezik:Inglês
Izdano: AME Publishing Company 2020
Teme:
Original Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7290551/
https://ncbi.nlm.nih.gov/pubmed/32566610
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/atm.2020.03.71
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items